Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo controlled, randomized study of dose-ranging safety,
tolerability, exploratory efficacy of adjunctive EQU-001 for seizures using the continuous
reassessment method in patients diagnosed with epilepsy.